Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Starting retirement planning at 60 can present unique challenges. Learn how to effectively navigate this stage for a secure future.
20,891 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
In June, Strategy, Inc. faced a sharp decline as crypto markets moved. This guide uncovers the drivers behind the dro...
The Ethereum Foundation lays out a 2026 roadmap centered on post-quantum security and bigger gas limits, reorganizing...
Investors eye the physical ai’s trillion opportunity—a potential $50 trillion payoff from industrial AI—but it requir...
Lenders are tightening terms on construction loans in early 2026, forcing builders to reevaluate finance leadership. ...
An investor-oriented deep dive into Lyft's leadership under David Risher and how the MiB framework guides growth, eff...
The market loves dramatic headlines about AI threatening legacy tech, but the real story is nuanced. This piece expla...
As Joby Aviation gears up for commercial flights in 2026, investors are weighing a bold ramp in production, regulator...
As Omada Health eyes the 2025 earnings journey, investors want a clear read on growth, margins, and risks. This guide...
A landmark revenue milestone meets a strategic investment push. This article breaks down why the billboard giant’s $1...
Jack Schlossberg, JFK’s grandson and Manhattan candidate, says Democrats lost touch with young men and explains why h...
New Mexico moves to examine decades of coerced sterilizations in Native communities, with findings due by 2027. The i...